Lymphoma Clinical Trials

36 trials recruiting in Canada.

Cancer

Recruiting Drug Device Behavioral Older adults Healthy volunteers

29 trials

Comparing Zilovertamab vedotin with Vincristine for diffuse large b-cell lymphoma

Explore this study →

There are 2 groups in this study. Group A receives Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone, together with one or more of: Rituximab Biosimilar, Prednisolone, Rescue medication and Methylprednisolone. Group B, the comparison group, receives Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone, together with one or more of: Rituximab Biosimilar, Prednisolone and Methylprednisolone.

Sites in Edmonton, Halifax and 3 more cities

Phase 3
2 groups
Sites in Edmonton, Halifax and 3 more cities
Recruiting

Official title: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Diffuse Large B-Cell Lymphoma · Merck Sharp & Dohme LLC

Comparing KITE-753 with Axicabtagene Ciloleucel for relapsed or refractory large b-cell lymphoma

Explore this study →

There are 2 groups in this study. Group A receives KITE-753, together with one or more of: Fludarabine and Cyclophosphamide. Group B receives Axicabtagene Ciloleucel, together with one or more of: Fludarabine and Cyclophosphamide.

Sites in Montreal and Québec

Phase 3
2 groups
Sites in Montreal and Québec
Recruiting

Official title: Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Relapsed or Refractory Large B-cell Lymphoma · Kite, A Gilead Company

Comparing Odronextamab with Rituximab for follicular lymphoma (FL)

Explore this study →

There are 2 groups in this study. Group A receives Odronextamab. Group B, the comparison group, receives Rituximab, together with one or more of: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone and Bendamustine.

Sites in Calgary, Greenfield Park and 3 more cities

Phase 3
2 groups
Sites in Calgary, Saint John and 3 more cities
Recruiting

Official title: A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Follicular Lymphoma (FL) · Regeneron Pharmaceuticals

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for lymphoma.

Comparing 3 approaches for DLBCL - diffuse large b cell lymphoma

Explore this study →

There are 4 groups in this study. Group A receives no study treatment and is followed for comparison. Groups B and D receive Cyclophosphamide, together with one or more of: TLI. Group C receives Cyclophosphamide.

One site, in Toronto

Phase 1
4 groups
One site, in Toronto
Recruiting

Official title: Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta

DLBCL - Diffuse Large B Cell Lymphoma · University Health Network, Toronto

Comparing CPA with DPX-Survivac for relapsed diffuse large b-cell lymphoma

Explore this study →

There are 2 groups in this study. Group A receives DPX-Survivac, Pembrolizumab and CPA. Group B receives DPX-Survivac and Pembrolizumab.

One site, in Saskatoon

Phase 2
2 groups
One site, in Saskatoon
Recruiting

Official title: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed Diffuse Large B-cell Lymphoma · ImmunoVaccine Technologies, Inc. (IMV Inc.)

Comparing Bleomycin with Brentuximab vedotin for Hodgkin lymphoma

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives one or more of: Involved site radiotherapy, Doxorubicin, Bleomycin, Vinblastine and Dacarbazine. Group B receives one or more of: Involved site radiotherapy, Doxorubicin, Brentuximab vedotin, Vinblastine, Dacarbazine and Haematopoietic growth factor.

Sites in Halifax, Hamilton and 5 more cities

Phase 3
2 groups
Sites in Halifax, Hamilton and 5 more cities
Recruiting

Official title: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Hodgkin Lymphoma · University College, London

Comparing 5 approaches for b-cell non-hodgkin lymphoma

Explore this study →

There are 5 groups in this study. Groups A, B, C, D and E receive IKS03.

One site, in Montreal

Phase 1
5 groups
One site, in Montreal
Recruiting

Official title: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

B-cell Non-Hodgkin Lymphoma · Iksuda Therapeutics Ltd.

Comparing Golcadomide with Lenalidomide for follicular lymphoma

Explore this study →

There are 2 groups in this study. Group A receives Golcadomide and Rituximab. Group B, the comparison group, receives Rituximab and Lenalidomide, together with one or more of: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone and Bendamustine.

Sites in Sherbrooke, Québec and 2 more cities

Phase 3
2 groups
Sites in Victoria, Toronto and 2 more cities
Recruiting

Official title: A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Follicular Lymphoma · Celgene

Testing Surovatamig for b-cell non-hodgkin lymphoma

Explore this study →

There are 2 groups in this study. Groups A and B receive Surovatamig.

Sites in Barrie, Brampton and 2 more cities

Phase 2
2 groups
Sites in Barrie, Brampton and 2 more cities
Recruiting

Official title: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

B-cell Non-Hodgkin Lymphoma · AstraZeneca

Testing zamtocabtagene autoleucel with Cyclophosphamide for refractory diffuse large b cell lymphoma (DLBCL)

Explore this study →

Everyone in this study is in one group, which receives one or more of: zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine and Bendamustine.

Sites in Edmonton and Toronto

Phase 2
1 group
Sites in Edmonton and Toronto
Recruiting

Official title: DALY II USA/ MB-CART2019.1 for DLBCL

Refractory Diffuse Large B Cell Lymphoma (DLBCL) · Miltenyi Biomedicine GmbH

Comparing 5 approaches for peripheral t cell lymphoma

Explore this study →

There are 5 groups in this study. Groups A and B, the comparison group, receive one or more of: Belinostat Injection and CHOP. Groups C and D, the comparison group, receive one or more of: Pralatrexate Injection and COP. Group E, the comparison group, receives CHOP.

Sites in Ottawa and Toronto

Phase 3
5 groups
Sites in Ottawa and Toronto
Recruiting

Official title: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Peripheral T Cell Lymphoma · Acrotech Biopharma Inc.

Comparing 3 approaches for large b-cell lymphoma

Explore this study →

There are 3 groups in this study. Groups A and C receive R-mini-CHOP and AZD0486. Group B, the comparison group, receives R-mini-CHOP.

Sites in Calgary, Hamilton and 2 more cities

Phase 3
3 groups
Sites in Calgary, Victoria and 2 more cities
Recruiting

Official title: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

Large B-cell Lymphoma · AstraZeneca

Testing Obinutuzumab with Glofitamab for b-cell non-hodgkins lymphoma

Explore this study →

Everyone in this study is in one group, which receives one or more of: Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin.

Sites in Calgary and Winnipeg

Phase 2
1 group
Sites in Calgary and Winnipeg
Recruiting

Official title: A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkins Lymphoma · Hoffmann-La Roche

Comparing 4 approaches for relapsed/refractory (r/r) mature b cell non Hodgkin

Explore this study →

There are 4 groups in this study. Groups A and B receive ARV-393. Groups C and D receive one or more of: ARV-393 and Glofitamab.

Sites in Calgary, Montreal and 1 more city

Phase 1
4 groups
Sites in Calgary, Toronto and 1 more city
Recruiting

Official title: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) · Arvinas Inc.

Testing glofitamab for diffuse large b cell lymphoma (DLBCL)

Explore this study →

There are 2 groups in this study. Group A receives no study treatment and is followed for comparison. Group B receives glofitamab.

Sites in Toronto and Montreal

Phase 2
2 groups
Sites in Toronto and Montreal
Recruiting

Official title: Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Diffuse Large B Cell Lymphoma (DLBCL) · University Health Network, Toronto

Testing Pembrolizumab with Bendamustine Hydrochloride for classical Hodgkin lymphoma

Explore this study →

Everyone in this study receives Pembrolizumab, together with one or more of: Bendamustine Hydrochloride.

One site, in Toronto

Phase 2
1 group
One site, in Toronto
Recruiting

Official title: Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Classical Hodgkin Lymphoma · University Health Network, Toronto

Comparing Gemcitabine with Brentuximab vedotin for Hodgkin lymphoma

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives one or more of: Gemcitabine, Dexamethasone and Cisplatin. Group B, the comparison group, receives Brentuximab vedotin and Pembrolizumab.

Sites in Montreal, Calgary and 9 more cities

Phase 2
2 groups
Sites in Calgary, Vancouver and 9 more cities
Recruiting

Official title: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma · Canadian Cancer Trials Group

Comparing Soquelitinib with Belinostat for not otherwise specified peripheral t-cell lymphoma

Explore this study →

There are 2 groups in this study. Group A receives Soquelitinib. Group B, the comparison group, receives one or more of: Belinostat and Pralatrexate.

Sites in Ottawa, Toronto and 1 more city

Phase 3
2 groups
Sites in Vancouver, Ottawa and 1 more city
Recruiting

Official title: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise Specified · Corvus Pharmaceuticals, Inc.

Testing Zanubrutinib with Sonrotoclax for mantle cell lymphoma

Explore this study →

Everyone in this study receives Zanubrutinib and Sonrotoclax, together with one or more of: CAR-T Cell Therapy.

Sites in Edmonton, Toronto and 1 more city

Phase 2
1 group
Sites in Edmonton, Vancouver and 1 more city
Recruiting

Official title: Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Mantle Cell Lymphoma · Canadian Cancer Trials Group

Testing Methotrexate with Rituximab (where available) for non-hodgkin lymphoma

Explore this study →

Everyone in this study receives Methotrexate and Ibrutinib, together with one or more of: Rituximab (where available).

Sites in Calgary, Hamilton and 6 more cities

Phase 2
1 group
Sites in Calgary, Vancouver and 6 more cities
Recruiting

Official title: Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Non-hodgkin Lymphoma · Canadian Cancer Trials Group

Testing TBI-2001 with Cyclophosphamide for relapsed or refractory CD19+ b-cell lymphoma

Explore this study →

Everyone in this study is in one group, which receives one or more of: TBI-2001, Cyclophosphamide and Fludarabine.

One site, in Toronto

Phase 1
1 group
One site, in Toronto
Recruiting

Official title: Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Relapsed or Refractory CD19+ B-cell Lymphoma · University Health Network, Toronto

Comparing 3 approaches for non-hodgkin lymphoma

Explore this study →

There are 3 groups in this study. Groups A, B and C receive LY4152199 - IV.

Sites in Montreal, Toronto and 1 more city

Phase 1
3 groups
Sites in Montreal, Toronto and 1 more city
Recruiting

Official title: A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Lymphoma, Non-Hodgkin · Eli Lilly and Company

Comparing 3 approaches for untreated follicular lymphoma

Explore this study →

There are 3 groups in this study. Groups A and B receive Surovatamig. Group C, the comparison group, receives one or more of: R-CHOP, R-CVP and BR.

Sites in Barrie, Chicoutimi and 8 more cities

Phase 3
3 groups
Sites in Winnipeg, Halifax and 8 more cities
Recruiting

Official title: A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Untreated Follicular Lymphoma · AstraZeneca

Comparing 3 approaches for large b-cell lymphoma

Explore this study →

There are 4 groups in this study. Group A receives Tislelizumab. Group B receives Zanubrutinib. Group C receives Tislelizumab + Zanubrutinib. …and 1 more groups.

One site, in Toronto

Phase 2
4 groups
One site, in Toronto
Recruiting

Official title: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

Large B-cell Lymphoma · University Health Network, Toronto

Comparing Obinutuzumab with Rituximab for lymphoma

Explore this study →

There are 2 groups in this study. Group A receives Glofitamab, together with one or more of: Obinutuzumab and Tocilizumab. Group B, the comparison group, receives one or more of: Rituximab, Bendamustine, Lenalidomide and Tocilizumab.

Sites in London, Ottawa and 1 more city

Phase 3
2 groups
Sites in London, Ottawa and 1 more city
Recruiting

Official title: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma · Hoffmann-La Roche

Comparing TLN-121 with zeprumetostat for lymphoma

Explore this study →

There are 2 groups in this study. Group A receives TLN-121. Group B receives one or more of: zeprumetostat (TLN-254) and TLN-121.

One site, in Vancouver

Phase 1
2 groups
One site, in Vancouver
Recruiting

Official title: TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Lymphoma · Treeline Biosciences, Inc.

Comparing cemacabtagene ansegedleucel with Foresight CLARITY™ IUO MRD test, for large b-cell lymphoma

Explore this study →

There are 2 groups in this study. Group A receives cemacabtagene ansegedleucel, together with one or more of: Fludarabine, Cyclophosphamide and Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™. Group B receives Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™.

Sites in Montreal, Calgary and 3 more cities

Phase 2
2 groups
Sites in Calgary, Halifax and 3 more cities
Recruiting

Official title: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Large B-cell Lymphoma · Allogene Therapeutics

Comparing 3 approaches for relapsed and/or refractory b-cell lymphoma

Explore this study →

There are 3 groups in this study. Group A receives KITE-363, together with one or more of: Cyclophosphamide and Fludarabine. Groups B and C receive KITE-753, together with one or more of: Cyclophosphamide and Fludarabine.

2 sites in Montreal

Phase 1
3 groups
2 sites in Montreal
Recruiting

Official title: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Relapsed and/or Refractory B-cell Lymphoma · Kite, A Gilead Company

Comparing 14 approaches for non-hodgkin lymphoma

Explore this study →

There are 14 groups in this study. Group A receives Axitinib. Group B receives Bosutinib. Group C receives Crizotinib. …and 11 more groups.

Sites in Edmonton, Kelowna and 8 more cities

Phase 2
14 groups
Sites in Edmonton, Kelowna and 8 more cities
Recruiting

Official title: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Lymphoma, Non-Hodgkin · Canadian Cancer Trials Group

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Lymphoma trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.